FibroBiologics公司宣布,其用于治疗糖尿病足溃疡的研究性药物Ciwc628的1/2期临床试验已取得进展,进入患者给药阶段。这一步骤标志着该疗法在临床开发路径上的重要推进。
FibroBiologics公司宣布,其用于治疗糖尿病足溃疡的研究性药物Ciwc628的1/2期临床试验已取得进展,进入患者给药阶段。这一步骤标志着该疗法在临床开发路径上的重要推进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.